Werewolf Therapeutics, Inc. Form 4 Filings

Werewolf Therapeutics director Luke Evnin reported that affiliated investment entities sold 157,084 shares of Werewolf Therapeutics common stock in an open-market transaction at a weighted average price of $0.30 per share. The sales were executed on behalf of several MPM-managed entities under a Rule 10b5-1 trading plan dated March 26, 2026. Following the transactions, these entities together held 143,199 shares indirectly associated with Evnin, and he disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.

Werewolf Therapeutics, Inc. insider filings report that investment funds associated with RA Capital completed open-market sales of common stock. The sales covered a total of 416,911 shares at a weighted average price of $0.35 per share, with individual trades between $0.34 and $0.39.

After these sales, one RA Capital-related fund held 303,719 shares of Werewolf Therapeutics common stock, while another related fund held 4,268,448 shares. The reporting parties, including RA Capital Management, its general partner, and certain individuals, disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interest.

Entities associated with RA Capital Management reported open-market sales of Werewolf Therapeutics common stock. RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. sold a combined 448,836 shares over June 12–16, 2026 at weighted average prices around $0.37–$0.40 per share.

After these transactions, one fund reported holdings of 331,414 shares and the other reported 4,657,664 shares, indicating they continue to hold a large position. The adviser and related parties disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

RA Capital–managed funds reported open-market sales of Werewolf Therapeutics, Inc. common stock. RA Capital Healthcare Fund LP and RA Capital Nexus Fund II LP sold a combined 678,226 shares of HOWL between June 9 and June 11, 2026 at weighted average prices around $0.37–$0.38 per share.

After these transactions, entities affiliated with RA Capital reported indirect ownership of about 5.4 million shares in total. Footnotes state that RA Capital Management, its general partner, and Dr. Peter Kolchinsky and Mr. Rajeev Shah disclaim beneficial ownership beyond their respective pecuniary interests.

Werewolf Therapeutics, Inc. reported an insider transaction involving entities associated with director Luke Evnin. These entities executed an open-market sale of 76,928 shares of common stock at a weighted average price of $0.37 per share, pursuant to a pre-established Rule 10b5-1 trading plan dated March 26, 2026.

The shares were sold across several MPM-affiliated investment entities and, following the transaction, those entities collectively held 300,283 shares of Werewolf Therapeutics common stock. Evnin reports these holdings indirectly and disclaims beneficial ownership except to the extent of his pecuniary interest.

Werewolf Therapeutics director-affiliated entities reported open-market sales of 105,565 shares of common stock. The transactions occurred on June 4, 5 and 8, 2026 at weighted average prices around $0.40 per share, within disclosed price ranges from $0.3706 to $0.454.

The sales were made by investment entities associated with Luke Evnin and were effected under a pre-established Rule 10b5-1 trading plan dated March 26, 2026. After these transactions, those entities collectively held 377,211 shares of Werewolf Therapeutics common stock, with Evnin disclaiming beneficial ownership beyond his pecuniary interest.

Werewolf Therapeutics director-affiliated funds reported open-market sales of 139,803 shares of Common Stock over three days. Entities associated with Luke Evnin sold 80,459 shares on June 1 at a weighted average price of $0.47, 29,595 shares on June 2 at $0.45, and 29,749 shares on June 3 at $0.42 per share.

The transactions were executed pursuant to a Rule 10b5-1 trading plan dated March 26, 2026, and are reported as indirect ownership. After the June 3 transactions, the affiliated entities collectively held 482,776 shares, and Evnin disclaims beneficial ownership except to the extent of his pecuniary interest.

Entities affiliated with Werewolf Therapeutics director Luke Evnin sold 141,106 shares of common stock in open-market transactions. The sales occurred over three days at weighted average prices of about $0.48, $0.46 and $0.45 per share, with individual trades ranging between $0.44 and $0.49705.

The trades were executed under a pre-established Rule 10b5‑1 trading plan dated March 26, 2026. After these transactions, entities associated with Evnin indirectly hold 622,579 shares of Werewolf Therapeutics common stock, spread across several MPM investment vehicles.

Werewolf Therapeutics director-related entities reported open-market sales of common stock. Investment entities associated with Luke Evnin sold a total of 191,762 shares of Werewolf Therapeutics, Inc. common stock in three open-market transactions on May 21, May 22 and May 26, 2026, at reported prices of $0.42, $0.45 and $0.47 per share, respectively. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 26, 2026. After these sales, the entities collectively held 763,685 shares indirectly, spread across several MPM-managed funds and LLCs.

Werewolf Therapeutics, Inc. director Luke Evnin reported three indirect open-market sales of Common Stock by affiliated investment entities. Across May 18–20, 2026, these entities sold a total of 171,049 shares at reported weighted average prices of $0.50, $0.45 and $0.43 per share. The trades were effected under a Rule 10b5-1 trading plan dated March 26, 2026. After these sales, the affiliated entities together held 955,447 shares, and Evnin disclaims beneficial ownership beyond his pecuniary interest.

Werewolf Therapeutics director-affiliated entities reported an open-market sale of company stock. Entities associated with Luke Evnin sold 44,679 shares of Werewolf Therapeutics common stock at a weighted average price of $0.54 per share in an open-market transaction. The sale was executed on May 13, 2026 under a pre-arranged Rule 10b5-1 trading plan dated March 26, 2026. After this transaction, these entities collectively held 1,126,496 shares indirectly, allocated among several MPM investment vehicles. Evnin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Werewolf Therapeutics, Inc. director-associated investment entities reported open-market sales of an aggregate 407,574 shares of Common Stock in three transactions. The sales occurred on May 8, May 11, and May 12 at weighted average prices of $0.70, $0.67, and $0.64 per share, respectively. After these transactions, entities associated with Luke Evnin collectively held 1,171,175 shares indirectly. The filing notes the trades were effected under a pre-established Rule 10b5-1 trading plan, indicating they were pre-planned rather than discretionary.

Werewolf Therapeutics, Inc. insider affiliates of RA Capital reported open-market sales of an aggregate 565,167 shares of Common Stock of HOWL. The trades occurred on May 8, 11 and 12, 2026 at weighted average prices around $0.64 per share, with detailed ranges from $0.62 to $0.76 disclosed.

The shares were sold indirectly through RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., with RA Capital Management, L.P. acting as investment manager. Following the latest transactions, one account held 406,282 shares and another held 5,709,858 shares of Common Stock indirectly. The Adviser, its general partner and related individuals disclaim beneficial ownership except to the extent of any pecuniary interest.

Werewolf Therapeutics director Luke Evnin reported indirect open-market sales of the company’s common stock by affiliated investment funds. Over May 5–7, 2026, entities including MPM Asset Management LLC and MPM BioVentures 2014, L.P. sold a total of 100,581 shares at weighted average prices around $0.63–$0.69 per share under a pre‑established Rule 10b5-1 plan dated March 26, 2026. After these transactions, the affiliated entities collectively hold 1,578,749 shares of Werewolf Therapeutics common stock, reported as indirect holdings. Evnin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Werewolf Therapeutics, Inc. director-related investment entities completed open-market sales of a total of 274,619 shares of common stock associated with Luke Evnin. The trades occurred on April 30, May 1 and May 4 at weighted average prices around $0.72–$0.73 per share.

The sales were executed by MPM Asset Management LLC and several MPM BioVentures and MPM Oncology Innovations funds pursuant to a Rule 10b5-1 trading plan dated March 26, 2026. After these transactions, the entities collectively hold 1,679,330 shares, which Evnin reports indirectly and for which he disclaims beneficial ownership beyond his pecuniary interest.

Entities associated with director Luke Evnin sold Werewolf Therapeutics, Inc. stock over three days under a pre-arranged plan. Investment vehicles including MPM Asset Management LLC, MPM BioVentures 2014 funds, MPM Asset Management Investors BV2014 LLC and MPM Oncology Innovations Fund, L.P. sold a total of 205,911 shares of Common Stock in open-market transactions on April 27, 28 and 29, 2026 at weighted average prices of $0.85, $0.73 and $0.69 per share, respectively.

After these indirect sales, the affiliated entities together held 1,953,949 shares. The filing notes the transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 26, 2026 and that Evnin disclaims beneficial ownership beyond his pecuniary interest.

Werewolf Therapeutics director–affiliated funds reported a small share sale. On January 16, 2026, investment entities associated with director Luke Evnin sold a total of 38,782 shares of Werewolf Therapeutics, Inc. common stock under a pre‑established Rule 10b5-1 trading plan dated September 24, 2025.

The weighted average sale price was $0.54 per share, with individual trades executed between $0.535 and $0.5495. The shares were sold by several MPM-managed entities, including AM LLC, MPM BioVentures 2014 funds, AM BV2014 and MPM Oncology Innovations Fund. After these transactions, entities associated with Evnin indirectly held 2,159,860 shares of Werewolf Therapeutics across these vehicles, and he disclaims beneficial ownership beyond his pecuniary interest.

Werewolf Therapeutics director Luke Evnin, through affiliated investment entities, reported indirect sales of common stock of Werewolf Therapeutics, Inc. over three trading days in January 2026. The transactions were executed under a pre-established Rule 10b5-1 trading plan dated September 24, 2025.

On January 13, 2026, affiliated entities sold 43,198 shares at a weighted average price of $0.55, leaving 2,266,671 shares indirectly beneficially owned. On January 14, 2026, they sold 30,616 shares at a weighted average price of $0.57, leaving 2,236,055 shares indirectly beneficially owned. On January 15, 2026, they sold 37,413 shares at a weighted average price of $0.55, leaving 2,198,642 shares indirectly beneficially owned.

The shares were held and sold by entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P. Evnin is associated with these entities and disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.

Werewolf Therapeutics director Luke Evnin reported indirect sales of the company’s common stock by affiliated investment entities, executed under a Rule 10b5-1 trading plan dated September 24, 2025. On January 8, 2026, these entities sold 7,716 shares at a weighted-average price of $0.63, on January 9 they sold 24,678 shares at a weighted-average price of $0.61, and on January 12 they sold 58,980 shares at a weighted-average price of $0.57, each across multiple trades within stated price ranges.

After these transactions, the affiliated entities collectively held 2,309,869 shares of Werewolf Therapeutics common stock indirectly. The shares are spread across several MPM-managed entities, and Evnin disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.

Werewolf Therapeutics director Luke Evnin, through affiliated investment entities, reported automatic sales of the company’s common stock under a Rule 10b5-1 trading plan dated September 24, 2025. On January 5, 2026, entities including MPM Asset Management LLC, MPM BioVentures 2014 funds, AM BV2014 and MPM Oncology Innovations Fund sold a total of 18,378 shares at a weighted average price of $0.64, leaving 2,453,919 shares indirectly held. On January 6, they sold 40,761 shares at a weighted average price of $0.65, with 2,413,158 shares indirectly held afterward. On January 7, they sold 11,915 shares at a weighted average price of $0.64, leaving 2,401,243 shares indirectly held. Evnin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Werewolf Therapeutics director Luke Evnin reported selling shares of the company’s common stock in three transactions carried out under a Rule 10b5-1 trading plan dated September 24, 2025. On December 15, 2025, affiliated investment entities sold a total of 23,640 shares at a weighted average price of $1.07. On December 16, 2025, they sold 14,548 shares at a weighted average price of $1.05, and on December 17, 2025, they sold 9,983 shares at a weighted average price of $1.14. Following these sales, Evnin reported 2,841,957 shares of Werewolf Therapeutics common stock beneficially owned indirectly through several MPM-managed entities.

Werewolf Therapeutics director Luke Evnin reported insider sales of the company’s common stock in mid-December 2025. On December 10, he reported selling 37,104 shares at a weighted average price of $1.06 per share through MPM-affiliated investment entities. On December 11 and 12, he reported additional sales of 28,009 and 17,858 shares at weighted average prices of $1.07 and $1.08, respectively, each executed in multiple trades within disclosed price ranges. These transactions were carried out under a Rule 10b5-1 trading plan dated September 24, 2025, and after the reported sales he indicated indirect beneficial ownership of 2,890,128 shares held across several MPM-managed funds.

Werewolf Therapeutics director reports planned stock sales

Luke Evnin, a director of Werewolf Therapeutics, Inc. (HOWL), reported three sales of common stock made under a Rule 10b5-1 trading plan dated September 24, 2025. On November 21, 2025, affiliated investment entities sold a total of 41,287 shares at a weighted average price of $0.83 per share. On November 24, 2025, they sold 56,992 shares at a weighted average price of $0.98 per share, and on November 25, 2025, they sold 27,297 shares at a weighted average price of $0.92 per share.

After these transactions, entities associated with Evnin beneficially owned a total of 3,287,551 HOWL shares across several MPM-managed funds and vehicles. The filing states that Evnin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Werewolf Therapeutics, Inc. (HOWL) reported insider stock sales by entities affiliated with MPM BioImpact, which is identified as a director and 10% owner group. On 11/21/2025, these affiliated funds sold 64,331 shares of common stock at a weighted average price of $0.83. On 11/24/2025, they sold another 88,802 shares at a weighted average price of $0.98, and on 11/25/2025 they sold 42,533 shares at a weighted average price of $0.92. The filing states that these trades were made under a Rule 10b5-1 trading plan dated September 24, 2025. After these transactions, the reporting group collectively held 5,125,770 shares of Werewolf Therapeutics common stock through various affiliated investment vehicles.

Werewolf Therapeutics, Inc. (HOWL) insider filing shows planned share sales by MPM-affiliated funds. A reporting group connected to MPM BioImpact and related investment vehicles sold 64,331 shares of common stock on 11/21/2025 at a weighted average price of $0.83, 88,802 shares on 11/24/2025 at $0.98, and 42,533 shares on 11/25/2025 at $0.92.

The sales were executed under a Rule 10b5-1 trading plan dated September 24, 2025, which is designed to pre-arrange trades. After these transactions, the reporting persons collectively report indirect beneficial ownership of 5,125,770 HOWL shares through several affiliated funds.

Werewolf Therapeutics director Luke Evnin reported a series of open-market sales of the company’s common stock under a pre-established Rule 10b5-1 trading plan dated September 24, 2025. On November 18, 2025, affiliated funds sold 33,776 shares at a weighted average price of $0.93, leaving 3,482,104 shares beneficially owned indirectly. On November 19, 2025, they sold 42,566 shares at a weighted average price of $0.94, leaving 3,439,538 shares. On November 20, 2025, they sold 26,411 shares at a weighted average price of $0.89, leaving 3,413,127 shares. The filing explains that the shares are held through various MPM-affiliated entities and that Evnin disclaims beneficial ownership beyond his pecuniary interest.

Werewolf Therapeutics, Inc. (HOWL) reported insider activity by MPM-affiliated entities on a Form 4. Investment vehicles associated with MPM BioImpact and related funds, which are reported as a director and 10% owner group, sold Werewolf Therapeutics common stock on three days under a pre-arranged Rule 10b5-1 trading plan dated September 24, 2025.

The group sold 52,627 shares on November 18, 2025 at a weighted average price of $0.93, 66,324 shares on November 19, 2025 at a weighted average price of $0.94, and 41,152 shares on November 20, 2025 at a weighted average price of $0.89. After these sales, they reported indirect beneficial ownership of 5,321,436 shares held across several MPM-managed entities, including MPM Asset Management LLC, MPM BioVentures 2014 funds, MPM Oncology Innovations Fund and UBS Oncology Impact Fund, with each reporting person disclaiming beneficial ownership beyond its pecuniary interest.

Werewolf Therapeutics, Inc. (HOWL) reported insider transactions by entities affiliated with MPM BioImpact LLC, which is identified as a director and 10% owner. Over three days, from 11/18/2025 to 11/20/2025, these reporting persons sold a total of 160,103 shares of common stock in open-market transactions. The weighted average sale prices were around $0.93 on 11/18, $0.94 on 11/19, and $0.89 on 11/20, with detailed price ranges provided for each day. After these sales, the reporting group continued to beneficially own 5,321,436 shares of Werewolf Therapeutics indirectly through multiple affiliated investment vehicles. The filing notes that the trades were executed under a Rule 10b5-1 trading plan dated September 24, 2025.

Werewolf Therapeutics (HOWL) director Luke Evnin reported a series of planned insider stock sales under a Rule 10b5-1 trading plan. On 11/13/2025, affiliated MPM entities sold 58,372 shares of common stock at a weighted average price of $0.98. On 11/14/2025, they sold 39,560 shares at a weighted average price of $0.93, and on 11/17/2025, they sold 36,621 shares at a weighted average price of $0.95. After these transactions, Evnin reported 3,515,880 shares of HOWL common stock beneficially owned indirectly through various MPM investment vehicles. The filing notes that prices are reported as weighted averages for multiple trades within specified price ranges.

Werewolf Therapeutics, Inc. (HOWL) reported insider stock sales by an affiliated director and 10% owner. Investment entities associated with MPM BioImpact LLC filed a Form 4 showing automatic sales of common stock under a Rule 10b5-1 trading plan dated September 24, 2025. On November 13, 2025, they sold 90,951 shares at a weighted average price of $0.98 per share, followed by 61,640 shares at $0.93 on November 14 and 57,061 shares at $0.95 on November 17. After these transactions, the group reported indirect beneficial ownership of 5,481,539 shares held across several MPM-managed funds, while disclaiming beneficial ownership beyond their economic interest. This filing is one of two identical submissions due to limits on the number of reporting persons.

Werewolf Therapeutics, Inc. (HOWL) director and 10% owner affiliated with MPM BioImpact reported planned insider stock sales. The filing covers three open‑market sales of Werewolf common stock executed under a Rule 10b5-1 trading plan dated September 24, 2025.

On November 13, 2025, the reporting group sold 90,951 shares at a weighted average price of $0.98. On November 14, 2025, they sold 61,640 shares at a weighted average price of $0.93, and on November 17, 2025, they sold 57,061 shares at a weighted average price of $0.95. Each day’s trades occurred across multiple prices within disclosed ranges.

After these transactions, the group reports indirect beneficial ownership of 5,481,539 Werewolf shares held through several affiliated investment vehicles, including MPM Asset Management LLC, MPM BioVentures 2014 funds, MPM Oncology Innovations Fund, and UBS Oncology Impact Fund.

Werewolf Therapeutics (HOWL) — Form 4 insider activity: Director Luke Evnin reported open‑market sales of company common stock executed under a Rule 10b5‑1 trading plan dated September 24, 2025. Sales occurred on four dates: 11/07/2025 (43,950 shares at a weighted average price of $1.11), 11/10/2025 (31,172 at $1.18), 11/11/2025 (35,818 at $1.14), and 11/12/2025 (26,101 at $1.09).

Following these transactions, the reported indirect beneficial holdings were updated to 3,743,524; 3,712,352; 3,676,534; and 3,650,433 shares, respectively. The holdings are indirect through affiliated entities (including AM LLC, BV 2014, BV 2014(B), AM BV2014, and MPM OIF), with a stated disclaimer of beneficial ownership beyond pecuniary interest.

Werewolf Therapeutics (HOWL): affiliated reporting persons led by MPM entities, identified as a director and 10% owner, reported open‑market sales executed under a Rule 10b5‑1 plan dated September 24, 2025. Sales occurred on November 7–12, 2025 across four days totaling 213,529 shares.

Disclosed transactions: 68,480 shares on 11/07 at a weighted average price of $1.11; 48,570 on 11/10 at $1.18; 55,810 on 11/11 at $1.14; and 40,669 on 11/12 at $1.09. Following these trades, the group reported 5,691,191 shares beneficially owned, held indirectly across multiple MPM-managed entities. Price ranges for the weighted averages were provided for each day, and the filing notes it is one of two identical filings due to reporting person limits.

Werewolf Therapeutics (HOWL): A director and 10% owner affiliated with MPM entities reported open‑market sales totaling 213,529 shares across 11/07–11/12/2025 under a Rule 10b5‑1 plan dated September 24, 2025. Weighted average prices by day were $1.11, $1.18, $1.14 and $1.09, with disclosed trade ranges spanning $1.065 to $1.21. Following these transactions, indirect beneficial ownership was 5,691,191 shares.

Werewolf Therapeutics (HOWL) director Luke Evnin reported open‑market sales totaling 155,885 shares on November 4–6, 2025 under a Rule 10b5‑1 trading plan established on September 24, 2025.

Weighted‑average sale prices were $1.22 on Nov 4 (range $1.17–$1.30), $1.22 on Nov 5 (range $1.19–$1.25), and $1.21 on Nov 6 (range $1.185–$1.27). Following these transactions, indirect beneficial holdings were 3,787,474 shares, held across multiple MPM‑affiliated entities. The filing notes the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.

Werewolf Therapeutics (HOWL): Insider transactions disclosed. An affiliated group led by MPM BioImpact reported open‑market sales of common stock on three dates under a Rule 10b5‑1 plan dated September 24, 2025.

Across 11/04/2025, 11/05/2025, and 11/06/2025, the group sold a combined 242,890 shares, at weighted‑average prices of $1.22, $1.22, and $1.21, respectively. Reported price ranges were $1.17–$1.30, $1.19–$1.25, and $1.185–$1.27. Following these transactions, the reporting persons indirectly beneficially owned 5,904,720 shares.

The filing notes the reporting person is a director and 10% owner, and that sales were allocated among affiliated entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P.

Werewolf Therapeutics (HOWL) reported insider stock sales by affiliated reporting persons. The group executed open‑market sales under a Rule 10b5‑1 plan dated September 24, 2025. Transactions included 140,488 shares on November 4 at a weighted average price of $1.22, 47,950 shares on November 5 at $1.22, and 54,452 shares on November 6 at $1.21.

Following these trades, the reporting persons collectively reported 5,904,720 shares beneficially owned on an indirect basis. The filing indicates the reporting persons are a director and 10% owner, and that the submission was made by more than one reporting person.

Werewolf Therapeutics (HOWL) director Luke Evnin reported open‑market sales of common stock made under a Rule 10b5‑1 plan dated September 24, 2025. The sales occurred on 10/30/2025, 10/31/2025, and 11/03/2025.

He sold 55,795 shares at a weighted average price of $1.43 (range $1.365–$1.55), 73,192 shares at $1.28 (range $1.205–$1.415), and 60,369 shares at $1.29 (range $1.245–$1.33). Following these transactions, 3,943,359 shares were reported as beneficially owned indirectly through affiliated entities.

Werewolf Therapeutics (HOWL): A reporting group affiliated with MPM BioImpact/MPM BioVentures, identified as a Director and 10% Owner, reported open‑market sales executed under a Rule 10b5‑1 plan dated September 24, 2025. The group sold 86,936 shares on 10/30/2025 at a weighted average price of $1.43, 114,044 shares on 10/31/2025 at $1.28, and 94,063 shares on 11/03/2025 at $1.29.

Following these transactions, the group reported indirect beneficial ownership of 6,355,717 shares, then 6,241,673 shares, and 6,147,610 shares, respectively. Footnotes state the sales were made across multiple affiliated entities, with price ranges of $1.365–$1.55 on 10/30, $1.205–$1.415 on 10/31, and $1.245–$1.33 on 11/03, and that each reporting person disclaims beneficial ownership beyond pecuniary interest.

Werewolf Therapeutics (HOWL): A director and 10% owner reported open‑market sales executed under a Rule 10b5‑1 plan dated September 24, 2025. The transactions were: 86,936 shares at a weighted average price of $1.43 on October 30, 2025; 114,044 shares at a weighted average price of $1.28 on October 31, 2025; and 94,063 shares at a weighted average price of $1.29 on November 3, 2025.

Following these sales, the filer reported 6,147,610 shares beneficially owned indirectly. The filing lists multiple affiliated entities as holders and confirms the plan‑based nature of the trades.

Werewolf Therapeutics (HOWL) director Luke Evnin reported open‑market sales of common stock executed under a Rule 10b5‑1 plan dated September 24, 2025.

He sold 46,664 shares on 10/27/2025 at a weighted average price of $1.72, 44,327 shares on 10/28/2025 at $1.64, and 86,154 shares on 10/29/2025 at $1.55. Following these transactions, he beneficially owned 4,132,715 shares indirectly.

Footnotes state the sales were made across affiliated entities and that prices reflect weighted averages with full trade‑level details available upon request.

Werewolf Therapeutics (HOWL): insider sales reported by MPM-affiliated holders. Reporting persons associated with MPM BioImpact/MPM BioVentures, identified as a Director and 10% Owner, disclosed open‑market sales executed pursuant to a Rule 10b5‑1 plan dated September 24, 2025.

Sales occurred on three dates: 72,709 shares on 10/27/2025 at a weighted average price of $1.72 (individual trades ranged $1.675–$1.82); 69,068 shares on 10/28/2025 at a weighted average price of $1.64 (range $1.605–$1.70); and 134,240 shares on 10/29/2025 at a weighted average price of $1.55 (range $1.51–$1.62).

Following these transactions, the reporting group’s beneficial ownership (indirect) was 6,645,961 shares after 10/27, 6,576,893 shares after 10/28, and 6,442,653 shares after 10/29, held across affiliated funds as detailed in the footnotes.

Werewolf Therapeutics (HOWL): Insider Form 4 filing reports sales by entities affiliated with MPM/UBS Oncology, identified as a director and 10% owner. The transactions were made pursuant to a Rule 10b5-1 plan dated September 24, 2025.

On October 27, 2025, 72,709 shares were sold at a weighted average price of $1.72 (range $1.675–$1.82), leaving 6,645,961 shares beneficially owned. On October 28, 2025, 69,068 shares were sold at a weighted average price of $1.64 (range $1.605–$1.70), leaving 6,576,893 shares beneficially owned. On October 29, 2025, 134,240 shares were sold at a weighted average price of $1.55 (range $1.51–$1.62), leaving 6,442,653 shares beneficially owned.

The filing attributes sales and post-transaction holdings across several affiliated funds and managers and notes that each reporting person disclaims beneficial ownership beyond their pecuniary interest.